Weak anti-SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients

  1. Ilies Benotmane
  2. Gabriela Gautier-Vargas
  3. Noelle Cognard
  4. Jerome Olagne
  5. Francoise Heibel
  6. Laura Braun-Parvez
  7. Jonas Martzloff
  8. Peggy Perrin
  9. Bruno Moulin
  10. Samira Fafi-Kremer
  11. Sophie Caillard
1 evaluations Published on
Read the full article Related papers
This article on Sciety

Abstract

Data concerning the anti-SARS-CoV-2 antibody response after mRNA COVID-19 vaccine in kidney transplant recipients (KTRs) are currently lacking. Here, we sought to examine this issue by analyzing the serological response observed in 241 KTRs after a first vaccine injection. Our results indicate that KTRs have a weak anti-SARS-CoV-2 antibody response, ultimately resulting in a low seroconversion rate (26/241, 10.8%). This phenomenon likely stems from a high immunosuppression burden in this clinical population.

Related articles

Related articles are currently not available for this article.